| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Comprehensive income (loss) | 620 | -1,927 | -9,220 | -15,723 |
| Net loss per common share - basic (in dollars per share) | 0 | -0.01 | -0.06 | -0.11 |
| Net loss per common share - diluted (in dollars per share) | 0 | -0.01 | -0.06 | -0.11 |
| Weighted average common shares outstanding - basic (in shares) | 163,649,932 | 159,459,413 | 152,445,935 | 148,993,823 |
| Weighted average common shares outstanding - diluted (in shares) | 177,617,307 | 159,459,413 | 152,445,935 | 148,993,823 |
Xeris Biopharma Holdings, Inc. (XERS)
Xeris Biopharma Holdings, Inc. (XERS)